Overview


According to FutureWise analysis the market for low density lipoprotein (ldl) test in 2023 is US$ 9.11 billion, and is expected to reach US$ 14.88 billion by 2031 at a CAGR of 6.32%.

Low-density lipoprotein ( LD) is among the five main groups of Lipoprotein. It transports all fat molecules throughout the body in extracellular fluid. From the least dense to the densest are chylomicrons, also known as ULDL (according to the overall density naming convention), extremely low-density Lipoproteins (VLDL), intermediate-density Lipoproteins (IDL), low and low-density lipsoproteins (LDL), and high-density Liposoproteins (HDL). LDL is responsible for delivering fat molecules to cells. LDL plays a role in atherosclerosis. This is when it is oxidized within arteries. Each LDL native particle allows emulsification. Each native LDL particle allows for emulsification, i.e. the ability to carry fatty acids in a container that is also water-soluble. Low-density lipoprotein, one of five types of lipoproteins that transport all fat molecules throughout the body through the extracellular fluid, is one of these five groups. This lipoprotein helps in marking fats that are available for receptor-mediated endocytosis. Because it increases fat in the arteries, extra low-density lipoprotein can be called bad cholesterol. This can cause the narrowing of blood vessels, which increases the risk of stroke, heart attack, and other diseases. Low-density lipoprotein (LDL) in blood vessels can be diagnosed using reagents, testing devices, and kits. N-generous LDL cholesterol calibrator, for example, can be used to determine bad cholesterol. The low-density lipoprotein test is used to determine the pathogenesis and severity of coronary heart disease.

People without a history of CVD can lower their risk of developing atherosclerotic heart disease (ASCVD), by reducing low-density cholesterol (LDL) through lifestyle changes or pharmacologic treatment. Primary prevention is a method of preventing CVD. LDL-C reduction can be based on observational and clinical trial evidence that patients with a wide range of LDL levels have lower CVD risk. CVD is defined as fatal or non-fatal myocardial injury, acute coronary syndromes, stroke, peripheral arterial disease, and coronary artery bypass surgery. LDL-C levels and the patient's 10-year risk of developing CVD are considered when deciding whether to lower LDL with pharmacotherapy. These factors guide the shared decision-making process (i.e., risk and benefits) between patients and their providers. Each LDL contains a hydrophobic core made up of polyunsaturated fatty acids, also known as linoleate, and hundreds to thousands (about 1500 are commonly cited as an example) of esterified as well as unesterified cholesterol molecules. The core is also home to a variety of triglycerides, and other fats, and is enclosed by a shell of unesterified cholesterol and phospholipids. LDL particles have a variable number of fatty acid molecules and therefore there is a distribution in their mass and sizes. Because of LDL's heterogeneous structure, it has been difficult to determine its structure. Recently, the structure of LDL at body temperature in natural conditions was described using a cryogenic electron microscope.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Low Density Lipoprotein (LDL) Test Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Low Density Lipoprotein (LDL) Test Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Randox Laboratories Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • Bio-rad Laboratories Inc
  • OPKO health Inc
  • Myriad Genetics Inc
  • Quest Diagnostics Inc
  • Eurofins Scientific
  • Linclin Diagnostics LLC
  • DiaSorin S.p.A
  • Boster Biological Technology Ltd
  • Rockland Immunochemicals Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Component

  • Kits
  • Reagents
  • Devices
  • Services

By Disease Type

  • Diabetes
  • Stroke
  • Obesity
  • Angina
  • Dyslipidaemia
  • Carotid Artery Disease

By End User

  • Hospitals
  • Clinics
  • Ambulatory Care
  • Research laboratory

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Low Density Lipoprotein (LDL) Test Market By Component, By Disease Type, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Low Density Lipoprotein (LDL) Test Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Low Density Lipoprotein (LDL) Test Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Low Density Lipoprotein (LDL) Test Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Low Density Lipoprotein (LDL) Test Market, By Component Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Kits
        2. Reagents
        3. Devices
        4. Services

  • 8.   Low Density Lipoprotein (LDL) Test Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diabetes
        2. Stroke
        3. Obesity
        4. Angina
        5. Dyslipidaemia
        6. Carotid Artery Disease

  • 9.   Low Density Lipoprotein (LDL) Test Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Ambulatory Care
        4. Research laboratory

  • 10.   North America Low Density Lipoprotein (LDL) Test Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Low Density Lipoprotein (LDL) Test Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Low Density Lipoprotein (LDL) Test Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Low Density Lipoprotein (LDL) Test Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Randox Laboratories Ltd
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Abbott Laboratories
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Danaher Corporation
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bio-rad Laboratories Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. OPKO health Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Myriad Genetics Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Quest Diagnostics Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Eurofins Scientific
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Linclin Diagnostics LLC
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. DiaSorin S.p.A
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Boster Biological Technology Ltd
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
            11.5. Strategic Overview
             12. Rockland Immunochemicals Inc
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
            12.4. Financial Overview
                 12.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients